From 2020 through 2022, PLWH with CVD, hypertension, or T2DM experienced a greater HCRU and cost burden than those without these comorbidities. The results highlight the need for individualized HIV care and tailored screening and risk modification interventions for CVD, hypertension, and T2DM.
No takes yet. Share an insight, caveat, or question.
Fleming et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: